As this signaling is very important in TNBC, a previously identified activator of AMPK and PPAR-α (peroxisome proliferator-activated receptor alpha) pathways and agonist of ADIPOR1, named AdipoRon [282], was proposed as a potential agent for the treatment of TNBC [206], as well as other cancers such as pancreatic malignancies, which are KMT2G-unrelated [283]. Here, ADIPOR1 is linked to cancer.